Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM4: Next Step – Asthma Uncontrolled With Medium-Dose ICS/LABA
2023-510458-18-00Phase 4Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 4, randomised, double-blind trial of dupilumab in asthma (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Annualized severe asthma exacerbation rate. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2023-510458-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510458-18-00.